Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting the protein essential to tumor cell growth and by adding a key signal to boost the immune system response. The findings are published in Cell Reports.
This article was originally published on MedicalXpress.com

